Neolys Develops Blood Test to Help Doctors Decide Radiotherapy Levels for Prostate Cancer

Neolys Develops Blood Test to Help Doctors Decide Radiotherapy Levels for Prostate Cancer
Neolys Diagnostics has developed a blood test to measure patients' sensitivity to radiation before they receive radiation therapy, a common prostate cancer treatment. The test helps doctors choose a radiation level that a patient's healthy tissue can withstand — so as little damage as possible is done to that tissue. Doctors have had few ways of judging that amount. More than half of prostate cancer patients receive radiotherapy, Neolys said. Although it is effective, a lot of patients experience unwanted side effects and severe damage to normal tissue. Bearing in mind that patients react differently to side effects and that their normal tissue can withstand different levels of radiation, Neolys identified biomarkers to measure healthy-tissue sensitivity to the treatment. It said its blood test can determine a patient’s risk of experiencing certain side effects within a couple of hours. “We are very proud of the performances of this new precise and rapid test," Julien Gillet-Daubin, chief executive officer of Neolys Diagnostics, said in a press release. "It is a significant breakthrough for patients and their physicians. A single drop of blood will be enough. This product opens a new paradigm in the practice of precision medicine in radiotherapy.” In related news, IsoRay announced that the U.S. Food and Drug Administration has
Subscribe or to access all post and page content.